615.2/ : , B-, AICAR (

Size: px
Start display at page:

Download "615.2/ : , B-, AICAR ("

Transcription

1 / : ,.. 1,.. 1,.. 1,.. 1,.. 1,.. 1,.. 2,.. 2,.. 2, , 2,,, : ,, 24;. +7(499) lantsova1979@mail.ru , B-, AICAR ( ),, ,., %- 10 %- Kollidon 17 PF, : -., , + 5 º , :,,, A.V. Lantsova 1, E.V. Sanarova 1, N.A. Oborotova 1, A.P. Poloskova 1, O.L. Orlova 1, E.V. Ignateva 1, I.V. Yartseva 1, A.S. Mironov 2, R.S. Shakulov 2, S.V. Yarotskiy 2, K.V. Lobanov 2 DEVELOPMENT OF TECHNOLOGY FOR INJECTABLE DOSAGE FORM BASED ON THE NATIONAL SUBSTANCE OF PURINE NUCLEOSIDE AKV-12 1 FSBSI «N.N. Blokhin Russian Cancer Research Center» FASO, Moscow 2 State Research Institute for Genetics and Selection of Industrial Microorganisms Abstract Overseas, a candidate for drugs for the treatment of B-cell chronic lymphocytic leukemia in on the second phase of clinical trials, a new drug AICAR (5-aminoimidazole-4-carboxamide ribonucleoside), an agonist of adenosine receptors selectively suppresses reproduction of tumor B-lymphocytes. In the Russian Federation Scientific Center Research Institute of Genetics and Selection of Industrial Microorganisms («Genetika») synthesized substance AKV-12 of purine nucleoside, which is also an agonist of adenosine receptors. This substance difficulty soluble in water, in this connection is the actual development of rational based injectable dosage form for cancer patients. In this regard, the aim of this study was to develop injectable substance for domestic dosage form AKV-12. In the study developed a parenteral dosage form based on the AKV-12 in the form of a lyophilisate for solution for injection. As co-solvents for the substance AKV-12 selected 5% mannitol solution and 10% solution of Kollidon 17 PF, solubilizing AKV times. Proposed adjuvants inhibiting reaction decay AKV-12: sodium metabisulfite, and ascorbic acid. It is shown that the stability of the AKV-12 in solution are strongly influenced by temperature. It is noted that the solution temperature is lowered to +5 º C, the degradation of the AKB 12 slows down 3 times. Developed the technology for production of dosage form AKV-12 as a lyophilisate for solution for injection, which allows you to increase the shelf life of the drug. Defined quality criteria of dosage form in accordance with the requirements of the current Russian Federation standard documentation for quality control of drugs. Key words: formulation, co-solvents, antioxidants, lyophilisation. - -, - -., RBG_3_2014.indd :27:28

2 34.,, , -,. -., , %.,,, (50 % ), - [1 3; 5; 6; 11; 14]. -, :,,, -, -,. -, - [1; 4; 7; 10; 13 16]. - B-, AICAR ( ), -, - [18; 19; 24; 25] [8; 9; 17]. -12, -, [12]. -12,, - 90 % [28], - - [27] P13K-Akt, [26],, - ERK Akt/mTOR/P70S6K [18] , [22; 25], [23], [24]. ES [19 23], - -12, -,, -, , - 12, ,. 258,2 /. ( ),., -,,. 1%- 7 7,5. -. Sartorius 2405 (Sartorius AG, ); - Sartorius LA1200S (Sartorius AG, - ); «Edwards Minifast DO.2» (Ero Electronic S.p.A., ); - Cary-100; - Sartorius PP-15 (Sartorius AG, ); - (Millipore, ); «Oxford», «Pipettor», 0,5 10 ;, ; - RZR 2021 Heidolph - PR 30 Heidolph (Heidolph, ) , , Stericup GP Millipore Express Plus, 0,22. - Minifast DO.2 (Edwards, ). -. -,, -. -,,, -, -,. -, RBG_3_2014.indd :27:28

3 35-12, 6 30, , ( ), ( 40 45). 3, ( ) Cary 100 (Varian, In., ) 267., ( 0,5 0,48 ) ±2 10, ( ) : D1 a0 V X D V 0 0 1, D 1 D 0-12 V 0-12 (20 000) V 1-12 (100) ,5 ( ) ph- HANNA 211 (Hanna Instruments, ) ,, /. -, -,., -, -,., ( ), Kollidon 17 PF, , (, ), Lutrol (BASF), (ISP, - ),,. (20±2), ,, (5 %- ) Kollidon 17 PF (10 %- ), (5 %- ) Kollidon 17 PF (10 %- ), (5 %- ). -12 Kollidon 17 PF 1 : 1; 1 : 2; 1 : 3; 1 : (9 %) 1 : 1, Kollidon 17 PF 1 : 2. - Kollidon 17 PF , - -12,, -.. 2, -12 -, -,. - -, -. -, - 7,5 (5 %- ),.., , ( + 25 ) ,, , ,, -12, - +5., : -12, Kollidon 17 PF,,, -, , -, -, , -,, RBG_3_2014.indd :27:29

4 , % 2,0 ( ) 5,0-5, ,0 - (2-10%) 8,0 - (2-10%) 8,0 9,0 - (5-20%) - (5-20%) 8,0-5% 8,0 - (5%) (10-20%) 8,0 9,0 - (5%) (10%) 8,0 9, (168 ), -12, % º + 5 º ,0 11,0 8, ,0 5,0 11,0 8, ,0 9, ,0 5,0 0, ,0 0,035 0, ,0 0,035 0,017 0,0007 5, ,0 0,035 0,017 0,0007 5, ,0 0,036 5, ,0 5,0 0, ,0 10,0 8,9 6,8 6,8 7,0 11,5 2,8 2,5 2,0 5,1 4,0 7, ( ),, ( ) -12, ( ), 11 ; ; Na 2 SO 4 0,48 1,98 0, ; ;. 0,48 1,98 0, ;. - ; NaHCO 3 0,48 1,98 0, ; ;. - ; NaHCO 3 ; 0,3 1,20 0,304 ;. - ; NaHCO 3 ; 0,3 0,90 0, ;. - 0,3 0,90 0, ; ; Na 2 SO 4 0,3 1,20 0, ,3 0,6 0,293 RBG_3_2014.indd :27:29

5 37-12, ( 5 : 7) º -, (-21:-23) º - -12, , : I -12 (5 %- ); 2-12 (5 %- ) (10 %- ) ; ( 5: 7), ( 21: 23). - 5 % ,,. -, ,5 ; 5,0 ; 5,5 ; ( 0,3-12 ) ( 50 40) ,, ,, -.,., -, ( ) -., :, 6, -,,, -. - (-40-45). - 2,5 3,5. -. ( 40 45) / , ,, (. 3). - «-12, 300» : 1 : PF 300,0 300,0 600,0 2,15 1,03 0,043-3 ( 300 ) «-12, 300». -12 «.» , I,. 1. 2, II, I, -, - : ( ); ; ; RBG_3_2014.indd :27:29

6 38 ; ; ; ; , -, , - 1,16 1,21 ; ±5 % ( XII,. 1,. 98), - - Y6 ( XII,. 1,. 93) ,0. ( XII,. 1,. 85) , - 1 XII,.1,. 176, 1,0 % ±2 (. 2) ,0015 %- -12.,,, (. 3). -, - -., -12, - 267± ,005 0,025 / %- Kollidon 17 PF, , - 12, -,, 2. -., º , : 1.. II.., // ,.. // LVI, 3 4. C ,.. // , RBG_3_2014.indd :27:29

7 ,..,... // , ,..,... // , ,..,.. - // , ,.., // , ,.., // , ,..,... - in vivo// , ,.. - // , ,..,... - // , ,..... :..., // , ,.. // , ,..,... // , ,..,... RU Baumann P., Mandl-Weber S., Emmerich B. et al. Activation of adenosine monophosphate activated protein kinase inhibits growth of multiple myeloma cells // Exp Cell Res P Campas C., Lopez J., Santidrian A. et al. Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes // Blood P Campas C., Santidrian A., Domingo A. et al. Acadesine induces apoptosis in B-cells from mantle cell lymphoma and splenic marginal zone lymphoma // Leukemia P Coll-Mulet L., Iglesias-Serret D., Santidrian A. et al. MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells // Blood P Garcia-Gil M., Pesi R., Perna S. et al. 5 -aminoimidazole-4-carboxamide riboside induces apoptosis in human neuroblastoma cells // Neuroscience P Kefas B., Heimberg H., Vaulont S. et al. AICA-riboside induces apoptosis of pancreatic beta cells through stimulation of AMP-activated protein kinase // Diabetologia P Meisse D., Van de Casteele M., Beauloye C. et al. Sustained activation of AMP-activated protein kinase induces c-jun N-terminal kinase activation and apoptosis in liver cells // FEBS Lett P Pesi R., Micheli V., Jacomelli G. et al. Cytosolic 5 -nucleotidase hyperactivity in erythrocytes of Lesch- Nyhan syndrome patients // Neuroreport P Rattan R., Giri S., Singh A., Singh I. et al.5-aminoimidazole-4-carboxamide-1-beta-d-ribofuranoside inhibits cancer cell proliferation in vitro and in vivo via AMP-activated protein kinase // J Biol Chem P Swinnen J., Beckers A., Brusselmans K. et al. Mimicry of a cellular low energy status blocks tumor cell anabolism and suppresses the malignant phenotype // Cancer Res P Xiang X., Saha A., Wen R. et al. AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms // Biochem Biophys Res Commun P / - RBG_3_2014.indd :27:30

5-aminoimidazole-4-carboxamide Riboside Induces Apoptosis Through AMP-activated Protein Kinase-independent and NADPH Oxidase-dependent Pathways

5-aminoimidazole-4-carboxamide Riboside Induces Apoptosis Through AMP-activated Protein Kinase-independent and NADPH Oxidase-dependent Pathways http://dx.doi.org/10.4110/in.2014.14.5.241 pissn 1598-2629 eissn 2092-6685 ORIGINAL ARTICLE 5-aminoimidazole-4-carboxamide Riboside Induces Apoptosis Through AMP-activated Protein Kinase-independent and

More information

Chinese Bulletin of Life Sciences AMP. (AMP-activated protein kinase, AMPK) Advances in the studies of AMP-activated protein kinase

Chinese Bulletin of Life Sciences AMP. (AMP-activated protein kinase, AMPK) Advances in the studies of AMP-activated protein kinase 17 2 2005 4 Chinese Bulletin of Life Sciences Vol. 17, No. 2 Apr., 2005 1004-0374(2005)02-0147-06 400038 AMP (AMP-activated protein kinase, ) AMP Q555.7 A Advances in the studies of AMP-activated protein

More information

Programa Cooperación Farma-Biotech

Programa Cooperación Farma-Biotech Programa Cooperación Farma-Biotech Jornada II: Oncología Early to mid-stage oncology developments: ATH001- Acadra Barcelona, 13 de abril de 2011 Programa Cooperación Farma-Biotech Jornada II: Oncología

More information

(14R)-14-hydroxy-4,14-retroretinol (14-HRR)

(14R)-14-hydroxy-4,14-retroretinol (14-HRR) Table S7 Atypical retinoids and retinoid-related molecules (RRMs) ame Chemical structure of the ligand(s) Mechanism of action and uses References Anhydroretinol (AR) Modulators of c-raf kinase 1-3 Blocks

More information

Clinical Biochemistry department/ College of medicine / AL-Mustansiriyah University

Clinical Biochemistry department/ College of medicine / AL-Mustansiriyah University Clinical Biochemistry department/ College of medicine / AL-Mustansiriyah University Dr. Ali al-bayati NUCLEOTIDE METABOLISM Lec. 3 The salvage pathway of purine synthesis Purines that result from the normal

More information

Obesity: The role of hypothalamic AMP-activated protein kinase in body weight regulation

Obesity: The role of hypothalamic AMP-activated protein kinase in body weight regulation The International Journal of Biochemistry & Cell Biology 37 (2005) 2254 2259 Medicine in focus Obesity: The role of hypothalamic AMP-activated protein kinase in body weight regulation Woo Je Lee, Eun Hee

More information

BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr.

BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr. BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES Overview and Mechanism of Action Dr. Leah Klapper, CSO 88 BL-8040: Novel CXCR4 Antagonist For Hematological Cancers Indications:

More information

The State Pharmacopoeia of the Russian Federation

The State Pharmacopoeia of the Russian Federation The State Pharmacopoeia of the Russian Federation XII Edition Part 1 Current state and strategy for the future Before 12 th edition of the State Pharmacopoeia of the Russian Federation there were following

More information

CURRICULUM VITAE. Bong Sook Jhun, Ph.D. DEGREE/YR/SUBJECT

CURRICULUM VITAE. Bong Sook Jhun, Ph.D. DEGREE/YR/SUBJECT CURRICULUM VITAE Bong Sook Jhun, Ph.D. EDUCATION AND TRAINING UNDERGRADUATE SCHOOL DATES MONTH/YEAR DEGREE/YR/SUBJECT Kyung Hee University 03/1995 02/1999 BS, 1999, Chemistry GRADUATE SCHOOL Kyung Hee

More information

AICA-Ribosiduria: A Novel, Neurologically Devastating Inborn Error of Purine Biosynthesis Caused by Mutation of ATIC

AICA-Ribosiduria: A Novel, Neurologically Devastating Inborn Error of Purine Biosynthesis Caused by Mutation of ATIC Am. J. Hum. Genet. 74:1276 1281, 2004 Report AICA-Ribosiduria: A Novel, Neurologically Devastating Inborn Error of Purine Biosynthesis Caused by Mutation of ATIC Sandrine Marie, 1 Bénédicte Heron, 2,3

More information

MDSC 1102/VM1102 Cardiovascular and Renal. Purine nucleotide metabolism

MDSC 1102/VM1102 Cardiovascular and Renal. Purine nucleotide metabolism MDSC 1102/VM1102 Cardiovascular and Renal Purine nucleotide metabolism Dr. J. Foster Biochemistry Unit, Dept. Preclinical Sciences Faculty of Medical Sciences, U.W.I. Learning Objectives Discuss purineand

More information

24 th November 2008 Glasgow eprints Service https://eprints.gla.ac.uk

24 th November 2008 Glasgow eprints Service https://eprints.gla.ac.uk Ewart, M-A. and Kohlhaas, C.F. and Salt, I.P. (2008) Inhibition of tumor necrosis factor α stimulated monocyte adhesion to human aortic endothelial cells by AMP-activated protein kinase. Arteriosclerosis,

More information

Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study

Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study Cancer Chemother Pharmacol (2013) 71:581 591 DOI 10.1007/s00280-012-2033-5 ORIGINAL ARTICLE Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II

More information

Nucleotide Metabolism Biochemistry by Lippincott pp

Nucleotide Metabolism Biochemistry by Lippincott pp Nucleotide Metabolism Biochemistry by Lippincott pp 291-306 Deoxyribonucleotides Synthesis 2'-deoxyribonucleotides: Nucleotides required for DNA synthesis Produced from ribonucleoside diphosphates by ribonucleotide

More information

Cancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous

Cancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous Session8 Medical Genetics Cancer Genetics J avad Jamshidi F a s a U n i v e r s i t y o f M e d i c a l S c i e n c e s, N o v e m b e r 2 0 1 7 What is Cancer? Uncontrolled growth of cells Not all tumors

More information

ABSTRACT: INTRODUCTION

ABSTRACT: INTRODUCTION /, Vol. 5, No. 3 Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-cd20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma Arnau Montraveta

More information

PRODUCT INFORMATION H 2

PRODUCT INFORMATION H 2 PRODUCT IFORMATIO ZOVIRAX COLD SORE CREAM APPROVED AME: Aciclovir COMPOSITIO: Aciclovir 5% w/w. DESCRIPTIO: Aciclovir is a synthetic acyclic purine nucleoside analogue. Its chemical name is 9-((2-hydroxyethoxy)methyl)guanine.

More information

Cancer prevalence. Chapter 7

Cancer prevalence. Chapter 7 Chapter 7 Cancer prevalence Prevalence measures the number of people diagnosed with cancer who are still alive. This chapter presents current and historical statistics on cancer prevalence in Ontario.

More information

Synthesis and Biological Evaluation of Protein Kinase D Inhibitors

Synthesis and Biological Evaluation of Protein Kinase D Inhibitors Synthesis and Biological Evaluation of Protein Kinase D Inhibitors Celeste Alverez Topic Seminar October 26, 2013 Celeste Alverez @ Wipf Group 10/26/2013 1 Protein Kinase D (PKD) A novel family of serine/threonine

More information

Phospho-AKT Sampler Kit

Phospho-AKT Sampler Kit Phospho-AKT Sampler Kit E 0 5 1 0 0 3 Kits Includes Cat. Quantity Application Reactivity Source Akt (Ab-473) Antibody E021054-1 50μg/50μl IHC, WB Human, Mouse, Rat Rabbit Akt (Phospho-Ser473) Antibody

More information

Clinical Policy: Idelalisib (Zydelig) Reference Number: CP.CPA.278 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Idelalisib (Zydelig) Reference Number: CP.CPA.278 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: (Zydelig) Reference Number: CP.CPA.278 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important

More information

Bifunctional enzyme ATIC promotes propagation of hepatocellular carcinoma by regulating AMPK-mTOR-S6 K1 signaling

Bifunctional enzyme ATIC promotes propagation of hepatocellular carcinoma by regulating AMPK-mTOR-S6 K1 signaling Li et al. Cell Communication and Signaling (2017) 15:52 DOI 10.1186/s12964-017-0208-8 RESEARCH Open Access Bifunctional enzyme ATIC promotes propagation of hepatocellular carcinoma by regulating AMPK-mTOR-S6

More information

Stage 4 bone cancer life expectancy

Stage 4 bone cancer life expectancy Stage 4 bone cancer life expectancy The Borg System is 100 % Stage 4 bone cancer life expectancy Stage 4 bone cancer survival rate (Prognosis). Is it possible to cure stage 4 bone cancer? What factors

More information

Zydelig. Zydelig (idelalisib) Description

Zydelig. Zydelig (idelalisib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.49 Subject: Zydelig Page: 1 of 6 Last Review Date: June 22, 2017 Zydelig Description Zydelig (idelalisib)

More information

Cancer Risk Factors in Ontario. Other Radiation

Cancer Risk Factors in Ontario. Other Radiation Cancer Risk Factors in Ontario Other Radiation OTHer radiation risk factor/ exposure Radon-222 and decay products X-radiation, gamma radiation Cancer The context where high risks were reported Magnitude

More information

7 Recruiting Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia Condition: Waldenstrom's Macroglobulinemia

7 Recruiting Carfilzomib, Rituximab and Dexamethasone in Waldenstrom's Macroglobulinemia Condition: Waldenstrom's Macroglobulinemia 1 Recruiting Questionnaire and Tissue Banking For Multiple Myeloma, Waldenstrom and Related Disorders Conditions: Multiple Myeloma; Waldenstrom's ; Smoldering Multiple Myeloma; Lymphoblastic Lymphoma Intervention:

More information

The incidence of type 2 diabetes is increasing. Long-Term AICAR Administration and Exercise Prevents Diabetes in ZDF Rats

The incidence of type 2 diabetes is increasing. Long-Term AICAR Administration and Exercise Prevents Diabetes in ZDF Rats Long-Term AICAR Administration and Exercise Prevents Diabetes in ZDF Rats Rasmus Pold, 1 Lasse S. Jensen, 1 Niels Jessen, 1 Esben S. Buhl, 1 Ole Schmitz, 1,2 Allan Flyvbjerg, 1 Nobuharu Fujii, 3 Laurie

More information

Leukemia And Lymphoma In The Nervous System

Leukemia And Lymphoma In The Nervous System Leukemia And Lymphoma In The Nervous System If you are searching for the book Leukemia and Lymphoma in the Nervous System in pdf format, then you've come to the right site. We presented complete variant

More information

Figure 1. Stepwise approach of treating patients with rheumatoid arthritis.

Figure 1. Stepwise approach of treating patients with rheumatoid arthritis. Establish diagnosis early Document baseline disease activity and damage Estimate prognosis Initiate therapy Begin patient education Start DMARD therapy within 3 months Consider NSAID Consider local or

More information

Metabolism of Nucleotides

Metabolism of Nucleotides Metabolism of Nucleotides Outline Nucleotide degradation Components of Nucleobases Purine and pyrimidine biosynthesis Hyperuricemia Sources Nucleotide degradation The nucleotides are among the most complex

More information

Zydelig. Zydelig (idelalisib) Description

Zydelig. Zydelig (idelalisib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.49 Subject: Zydelig Page: 1 of 6 Last Review Date: June 22, 2018 Zydelig Description Zydelig (idelalisib)

More information

Uveal Melanoma Cell Growth Is Inhibited by Aminoimidazole Carboxamide Ribonucleotide (AICAR) Partially Through Activation of AMP-Dependent Kinase

Uveal Melanoma Cell Growth Is Inhibited by Aminoimidazole Carboxamide Ribonucleotide (AICAR) Partially Through Activation of AMP-Dependent Kinase Retina Uveal Melanoma Cell Growth Is Inhibited by Aminoimidazole Carboxamide Ribonucleotide (AICAR) Partially Through Activation of AMP-Dependent Kinase Ahmad Al-Moujahed, 1 Fotini Nicolaou, 2 Katarzyna

More information

Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic

Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Immune checkpoint inhibitors in Hodgkin and non-hodgkin Lymphoma: How do they work? Where will we use them? Stephen M. Ansell, MD, PhD Mayo Clinic Conflicts of Interest Research Funding from Bristol Myers

More information

Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765

Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765 Contact: Ramses Erdtmann Vice President of Finance Phone: 408-215-3325 Pharmacyclics Reports Updated Clinical Results from its Phase IA Trial of its First in Human BTK- Inhibitor PCI-32765 Company to Host

More information

Effect of AMPK activation on muscle glucose metabolism in conscious rats

Effect of AMPK activation on muscle glucose metabolism in conscious rats Effect of AMPK activation on muscle glucose metabolism in conscious rats RAYNALD BERGERON, 1 RAYMOND R. RUSSELL III, 1 LAWRENCE H. YOUNG, 1 JIAN-MING REN, 2 MELISSA MARCUCCI, 1 AGNES LEE, 1 AND GERALD

More information

Dr. C. Tom Kouroukis. New and upcoming treatments for Lymphoma

Dr. C. Tom Kouroukis. New and upcoming treatments for Lymphoma Dr. C. Tom Kouroukis New and upcoming treatments for Lymphoma New and upcoming treatments for Lymphoma Dr. Tom Kouroukis Hamilton Convention Centre November 23, 2013 Overview Importance and design of clinical

More information

Basis and Clinical Applications of Interferon

Basis and Clinical Applications of Interferon Interferon Therapy Basis and Clinical Applications of Interferon JMAJ 47(1): 7 12, 2004 Jiro IMANISHI Professor, Kyoto Prefectural University of Medicine Abstract: Interferon (IFN) is an antiviral substance

More information

Intracellular signalling cascades associated with TRP channels

Intracellular signalling cascades associated with TRP channels Gerald Thiel Intracellular signalling cascades associated with TRP channels Current state of investigations and potential applications Saarland University, Germany Campus Saarbrücken Department of Medical

More information

A Review of Guidelines and Evidence for the Use of Irradiated Blood Products in Solid Tumor, Chemotherapy Patients. Chris Kim 11/29/12

A Review of Guidelines and Evidence for the Use of Irradiated Blood Products in Solid Tumor, Chemotherapy Patients. Chris Kim 11/29/12 A Review of Guidelines and Evidence for the Use of Irradiated Blood Products in Solid Tumor, Chemotherapy Patients Chris Kim 11/29/12 Background Prevention of TAGVHD Irradiation: induces DNA crosslinks,

More information

AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury

AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury Related Commentary, page 465 Research article AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury Raymond R. Russell III,

More information

NFκB What is it and What s the deal with radicals?

NFκB What is it and What s the deal with radicals? The Virtual Free Radical School NFκB What is it and What s the deal with radicals? Emily Ho, Ph.D Linus Pauling Institute Scientist Department of Nutrition and Food Management Oregon State University 117

More information

Prepared by: Dr.Mansour Al-Yazji

Prepared by: Dr.Mansour Al-Yazji C L L CLL Prepared by: Abd El-Hakeem Abd El-Rahman Abu Naser Ahmed Khamis Abu Warda Ahmed Mohammed Abu Ghaben Bassel Ziad Abu Warda Nedal Mostafa El-Nahhal Dr.Mansour Al-Yazji LEUKEMIA Leukemia is a form

More information

AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise

AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise Acta Physiol Scand 23, 78, 43 442 AMPK as a metabolic switch in rat muscle, liver and adipose tissue after exercise N. B. Ruderman, H. Park, V. K. Kaushik, D. Dean, S. Constant, M. Prentki 2 and A. K.

More information

ImmunoTools special Award 2014

ImmunoTools special Award 2014 ImmunoTools special Award 2014 Davide Ferrari, PhD University of Ferrara, Department of Morphology, Surgery and Experimental Medicine. Section of Pathology, Oncology and Exper. Biology via L. Borsari 46,

More information

Revolutionizing the Treatment of Cancer

Revolutionizing the Treatment of Cancer Revolutionizing the Treatment of Cancer June 2014 Safe Harbor Statement The statements that follow (including projections and business trends) are forward looking statements. Rexahn's actual results may

More information

Janssen Hematologic Malignancy Portfolio

Janssen Hematologic Malignancy Portfolio Janssen Hematologic Malignancy Portfolio Recorded Webcast: Update for Analysts and Investors January 216 Oncology 1 Safe Harbor Statement This webcast contains "forward-looking statements" as defined in

More information

Bendamustine for relapsed follicular lymphoma refractory to rituximab

Bendamustine for relapsed follicular lymphoma refractory to rituximab LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Bendamustine for relapsed follicular lymphoma refractory to rituximab Bendamustine for relapsed follicular lymphoma refractory to rituximab Contents Summary 1

More information

A medical nutriment supports dacarbazine treatment in stage III melanoma*

A medical nutriment supports dacarbazine treatment in stage III melanoma* A medical nutriment supports dacarbazine treatment in stage III melanoma* Running title: Medical nutriment in melanoma LV Demidov, V Manzjuk, GY Kharkevitch, NA Pirogova3 and EV Artamonova Melanoma Unit,

More information

Imbruvica. Imbruvica (ibrutinib) Description

Imbruvica. Imbruvica (ibrutinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.41 Subject: Imbruvica Page: 1 of 5 Last Review Date: June 22, 2017 Imbruvica Description Imbruvica

More information

Nucleotide Metabolism. Pyrimidine Met. Purine Met.

Nucleotide Metabolism. Pyrimidine Met. Purine Met. Nucleotide Metabolism Pyrimidine Met. Purine Met. Learning Objectives 1. How Are Purines Synthesized? 2. How Are Purines Catabolized? 3. How Are Pyrimidines Synthesized and Catabolized? 4. How Are Ribonucleotides

More information

Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017

Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017 Annual Flash Report (unaudited) Fiscal Year ended March 31, 2017 Supplemental nation Status of Development Pipeline as of May 8, 2017. Main Status of Development Pipelines (Oncology) 1. Development Status

More information

Targeting voltage-gated K + channels in cancer reveal new biochemical pathways and therapeutic opportunities

Targeting voltage-gated K + channels in cancer reveal new biochemical pathways and therapeutic opportunities July 7 th, 2015 Structure, Function and Engineering of Ion Channels Targeting voltage-gated K + channels in cancer reveal new biochemical pathways and therapeutic opportunities Saverio Gentile, Ph.D. Department

More information

Icd 10 code breast cancer in remission

Icd 10 code breast cancer in remission Icd 10 code breast cancer in remission Search 6-10-2011 I am stumped! I can't seem to find an ICD-9 code for breast cancer in remission. Does anyone know where to look? Thanks! 3-4-2014 ICD-10 Training.

More information

New formulas for successful drug delivery Hot-melt extrusion for enhanced solubility and bioavailability

New formulas for successful drug delivery Hot-melt extrusion for enhanced solubility and bioavailability New formulas for successful drug delivery Hot-melt extrusion for enhanced solubility and bioavailability Andreas Gryczke, an enabler in excipients Pharma Ingredients & Services. Welcome to more opportunities.

More information

PI3K Background. The SignalRx R & D pipeline is shown below followed by a brief description of each program:

PI3K Background. The SignalRx R & D pipeline is shown below followed by a brief description of each program: PI3K Background The phosphatidylinositol 3-kinase (PI3K) pathway is a key cell signaling node whose dysregulation commonly results in the transformation of normal cells into cancer cells. The role of PI3K

More information

Dr Muge Cevik. Chelsea and Westminster Hospital, London. 18 th Annual Conference of the British HIV Association (BHIVA)

Dr Muge Cevik. Chelsea and Westminster Hospital, London. 18 th Annual Conference of the British HIV Association (BHIVA) 18 th Annual Conference of the British HIV Association (BHIVA) Dr Muge Cevik Chelsea and Westminster Hospital, London 18-20 April 2012, The International Convention Centre, Birmingham A09 Polymorphisms

More information

IMBRUVICA (ibrutinib) oral capsule and tablet

IMBRUVICA (ibrutinib) oral capsule and tablet IMBRUVICA (ibrutinib) oral capsule and tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This

More information

Molecular Cell Biology. Prof. D. Karunagaran. Department of Biotechnology. Indian Institute of Technology Madras

Molecular Cell Biology. Prof. D. Karunagaran. Department of Biotechnology. Indian Institute of Technology Madras Molecular Cell Biology Prof. D. Karunagaran Department of Biotechnology Indian Institute of Technology Madras Module 9 Molecular Basis of Cancer, Oncogenes and Tumor Suppressor Genes Lecture 2 Genes Associated

More information

Crosstalk between Adiponectin and IGF-IR in breast cancer. Prof. Young Jin Suh Department of Surgery The Catholic University of Korea

Crosstalk between Adiponectin and IGF-IR in breast cancer. Prof. Young Jin Suh Department of Surgery The Catholic University of Korea Crosstalk between Adiponectin and IGF-IR in breast cancer Prof. Young Jin Suh Department of Surgery The Catholic University of Korea Obesity Chronic, multifactorial disorder Hypertrophy and hyperplasia

More information

Imbruvica. Imbruvica (ibrutinib) Description

Imbruvica. Imbruvica (ibrutinib) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.41 Subject: Imbruvica Page: 1 of 5 Last Review Date: September 15, 2017 Imbruvica Description Imbruvica

More information

Activation of AMPK is essential for AICAR-induced glucose uptake by skeletal muscle but not adipocytes

Activation of AMPK is essential for AICAR-induced glucose uptake by skeletal muscle but not adipocytes Am J Physiol Endocrinol Metab 282: E1239 E1244, 2002. First published February 19, 2002; 10.1152/ajpendo.00455.2001. Activation of AMPK is essential for AICAR-induced glucose uptake by skeletal muscle

More information

Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients

Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type 2 diabetic patients Diabetologia () 51:193 19 DOI 1.17/s15--11-7 ARTICLE Intravenous AICAR administration reduces hepatic glucose output and inhibits whole body lipolysis in type diabetic patients H. Boon & M. Bosselaar &

More information

Immune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich

Immune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3

More information

p53 and Apoptosis: Master Guardian and Executioner Part 2

p53 and Apoptosis: Master Guardian and Executioner Part 2 p53 and Apoptosis: Master Guardian and Executioner Part 2 p14arf in human cells is a antagonist of Mdm2. The expression of ARF causes a rapid increase in p53 levels, so what would you suggest?.. The enemy

More information

IBR-Phyto(flu)ene, COLORLESS CAROTENOIDS TECHNOLOGIY OVERVIEW

IBR-Phyto(flu)ene, COLORLESS CAROTENOIDS TECHNOLOGIY OVERVIEW PRODUCT CATALOG IBR-Phyto(flu)ene, COLORLESS CAROTENOIDS TECHNOLOGIY OVERVIEW Biologically, carotenoids are an important group of compounds with more than 700 members. are found widely throughout nature,

More information

Bihong Zhao, M.D, Ph.D Department of Pathology

Bihong Zhao, M.D, Ph.D Department of Pathology Bihong Zhao, M.D, Ph.D Department of Pathology 04-28-2009 Is tumor self or non-self? How are tumor antigens generated? What are they? How does immune system respond? Introduction Tumor Antigens/Categories

More information

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment

Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment Immune Checkpoint Inhibitors: The New Breakout Stars in Cancer Treatment 1 Introductions Peter Langecker, MD, PhD Executive Medical Director, Global Oncology Clinipace Worldwide Mark Shapiro Vice President

More information

La via del segnale PI3K/AKT/mTOR Inibitori di mtor nel carcinoma mammario

La via del segnale PI3K/AKT/mTOR Inibitori di mtor nel carcinoma mammario La via del segnale PI3K/AKT/mTOR Inibitori di mtor nel carcinoma mammario Alessandra Modena U.O.C. Oncologia Medica Direttore: Dott.ssa Stefania Gori Ospedale Sacro Cuore - Don Calabria 29 novembre 2016

More information

Revlimid. Revlimid (lenalidomide) Description. Section: Prescription Drugs Effective Date: October 1, 2016

Revlimid. Revlimid (lenalidomide) Description. Section: Prescription Drugs Effective Date: October 1, 2016 Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.47 Subject: Revlimid Page: 1 of 7 Last Review Date: September 15, 2016 Revlimid Description Revlimid

More information

NUCLEOTIDE METABOLISM

NUCLEOTIDE METABOLISM NUCLEOTIDE METABOLISM Purine and pyrimidine. The atoms are numbered according to the international system. Tautomerism of the oxo and amino functional groups of purines and pyrimidines. POLYNUCLEOTIDES

More information

Therapy: Metformin takes a new route to clinical

Therapy: Metformin takes a new route to clinical Therapy: Metformin takes a new route to clinical efficacy. Marc Foretz, Benoit Viollet To cite this version: Marc Foretz, Benoit Viollet. Therapy: Metformin takes a new route to clinical efficacy.. Nature

More information

CoQ10 and Cancer Treatment

CoQ10 and Cancer Treatment http://www.lef.org/ Life Extension Magazine September 2009 CoQ10 and Cancer Treatment By William Faloon For more than a decade, Life Extension has reported on small clinical studies that demonstrate beneficial

More information

Developing Best in Class BET Inhibitors for Oncology & AI: from Discovery to the Clinic. Kevin G. McLure, PhD EpiCongress July 2014

Developing Best in Class BET Inhibitors for Oncology & AI: from Discovery to the Clinic. Kevin G. McLure, PhD EpiCongress July 2014 Developing Best in Class BET Inhibitors for Oncology & AI: from Discovery to the Clinic Kevin G. McLure, PhD EpiCongress July 2014 Zenith Epigenetics Overview Formed from Resverlogix as an independent

More information

EP A2 (19) (11) EP A2 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2011/42

EP A2 (19) (11) EP A2 (12) EUROPEAN PATENT APPLICATION. (43) Date of publication: Bulletin 2011/42 (19) (12) EUROPEAN PATENT APPLICATION (11) EP 2 377 14 A2 (43) Date of publication: 19..11 Bulletin 11/42 (21) Application number: 10329.0 (1) Int Cl.: A61K 9/00 (06.01) A61K 31/13 (06.01) A61K 31/167

More information

Rapid Case Ascertainment in Population and Hospital- Based Studies: Notes From the Field

Rapid Case Ascertainment in Population and Hospital- Based Studies: Notes From the Field Rapid Case Ascertainment in Population and Hospital- Based Studies: Notes From the Field James R. Cerhan, M.D., Ph.D. Mayo Clinic College of Medicine University of Iowa College of Public Health Overview

More information

Global Metabolic Changes and Cellular Dysfunction in Diamide Challenged G6PD-Deficient Red Blood Cells. Dr. Daniel Tsun-Yee Chiu, Professor

Global Metabolic Changes and Cellular Dysfunction in Diamide Challenged G6PD-Deficient Red Blood Cells. Dr. Daniel Tsun-Yee Chiu, Professor Global Metabolic Changes and Cellular Dysfunction in Diamide Challenged G6PD-Deficient Red Blood Cells Dr. Daniel Tsun-Yee Chiu, Professor Graduate Institute of Medical Biotechnology, Chang Gung University,

More information

Development status of OPDIVO (nivolumab) 1

Development status of OPDIVO (nivolumab) 1 August 1, 2018 Development status of OPDIVO (nivolumab) 1 Target disease JAPAN US/EU KR/TW Melanoma (1 st ) Approved Approved Approved Melanoma (Adjuvant Therapy) Filing Approved (US) Non-small cell lung

More information

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL)

Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Non-Hodgkin lymphomas (NHLs) Hodgkin lymphoma )HL) Lymphoid Neoplasms: 1- non-hodgkin lymphomas (NHLs) 2- Hodgkin lymphoma 3- plasma cell neoplasms Non-Hodgkin lymphomas (NHLs) Acute Lymphoblastic Leukemia/Lymphoma

More information

Cancer Endorsement Maintenance 2011-Maintenance Measures

Cancer Endorsement Maintenance 2011-Maintenance Measures Measure Number Title Description Measure Steward 0210 Proportion receiving chemotherapy in the last 14 days of life 0211 Proportion with more than one emergency room visit in the last days of life 0212

More information

PARENTERAL PREPARATIONS

PARENTERAL PREPARATIONS PARENTERAL PREPARATIONS INTRODUCTION Parenteral (Gk, para enteron, beside the intestine) dosage forms differ from all other drug dosage forms, because they are injected directly into body tissue through

More information

Published Ahead of Print on June 15, 2017, as doi: /haematol Copyright 2017 Ferrata Storti Foundation.

Published Ahead of Print on June 15, 2017, as doi: /haematol Copyright 2017 Ferrata Storti Foundation. Published Ahead of Print on June 15, 2017, as doi:10.3324/haematol.2016.162958. Copyright 2017 Ferrata Storti Foundation. The prohibitin-binding compound fluorizoline induces apoptosis in chronic lymphocytic

More information

A Summary of the studies conducted with CV247

A Summary of the studies conducted with CV247 A Summary of the studies conducted with CV247 Introduction Several epidemiological studies have shown that people deficient in trace elements such as selenium, copper, manganese, and vitamins, mainly C,D

More information

Outlines. Disclosures. Updates on B-cell Chronic Lymphoproliferative Disorders of the Blood and Bone Marrow

Outlines. Disclosures. Updates on B-cell Chronic Lymphoproliferative Disorders of the Blood and Bone Marrow Updates on B-cell Chronic Lymphoproliferative Disorders of the Blood and Bone Marrow Sa A, Wang MD Jeffrey L. Jorgensen, MD, PhD Department of Hematopathology, UT M.D. Anderson Cancer Center, Houston,

More information

Second Generation BTK Inhibitors Acalabrutinib (ACP-196) and Zanubrutinib (BGB-3111)

Second Generation BTK Inhibitors Acalabrutinib (ACP-196) and Zanubrutinib (BGB-3111) Second Generation BTK Inhibitors Acalabrutinib (ACP-196) and Zanubrutinib (BGB-3111) Constantine (Con) S. Tam Director of Haematology, St Vincent s Hospital Melbourne; Lead for Chronic Lymphocytic Leukemia

More information

Impact of vitamin C on genistein-induced cell death in prostate cancer. Toluleke Oloruntobi Famuyiwa 09/20/2015

Impact of vitamin C on genistein-induced cell death in prostate cancer. Toluleke Oloruntobi Famuyiwa 09/20/2015 Impact of vitamin C on genistein-induced cell death in prostate cancer 1 st Electronic Conference on Molecular Science Toluleke Oloruntobi Famuyiwa 09/20/2015 Introduction Stages of Prostate Cancer Key

More information

One-two Punch to Deadly Pancreatic Cancer: Targeted Therapy with Mab AR9.6 and Rapamycin Analogue ACP Jan 2016

One-two Punch to Deadly Pancreatic Cancer: Targeted Therapy with Mab AR9.6 and Rapamycin Analogue ACP Jan 2016 One-two Punch to Deadly Pancreatic Cancer: Targeted Therapy with Mab AR9.6 and Rapamycin Analogue ACP 2127 Jan 2016 AmrutBio Overview A subsidiary of Quest PharmaTech, a publicly traded (QPT-TSXV), Canadian

More information

Potential Role of Sphingosine 1-Phosphate in the. Pathogenesis of Rheumatoid Arthritis

Potential Role of Sphingosine 1-Phosphate in the. Pathogenesis of Rheumatoid Arthritis Potential Role of Sphingosine 1-Phosphate in the Pathogenesis of Rheumatoid Arthritis COMMENTARY for Zhao, C., Fernandes, M.J., Turgeon, M., Tancrede, S., Di Battista, J., Poubelle, P.E. and Bourgoin,

More information

Novel Approach to the Potential Treatment of Patients with B-Cell Lymphomas Harboring the MYD88 L265P Mutation:

Novel Approach to the Potential Treatment of Patients with B-Cell Lymphomas Harboring the MYD88 L265P Mutation: Novel Approach to the Potential Treatment of Patients with B-Cell Lymphomas Harboring the MYD88 L265P Mutation: Combination Treatment with TLR Antagonist and Rituximab D. Wang, W. Jiang, T. Sullivan, L.

More information

Chemistry of Carbon. Building Blocks of Life

Chemistry of Carbon. Building Blocks of Life Chemistry of Carbon Building Blocks of Life 2013-2014 Why study Carbon? All of life is built on carbon Cells ~72% H 2 O ~25% carbon compounds carbohydrates lipids proteins nucleic acids ~3% salts Na, Cl,

More information

Protein kinases are enzymes that add a phosphate group to proteins according to the. ATP + protein OH > Protein OPO 3 + ADP

Protein kinases are enzymes that add a phosphate group to proteins according to the. ATP + protein OH > Protein OPO 3 + ADP Protein kinase Protein kinases are enzymes that add a phosphate group to proteins according to the following equation: 2 ATP + protein OH > Protein OPO 3 + ADP ATP represents adenosine trisphosphate, ADP

More information

Cigarette Smoke Exposure and HIV-Related Neurologic Disease Progression Basic Mechanisms and Clinical Consequences

Cigarette Smoke Exposure and HIV-Related Neurologic Disease Progression Basic Mechanisms and Clinical Consequences Cigarette Smoke Exposure and HIV-Related Neurologic Disease Progression Basic Mechanisms and Clinical Consequences Walter Royal, III, MD Professor of Neurology University of Maryland School of Medicine

More information

A holistic approach to targeting breast cancer part II: Micronutrient synergy. Presented by: Dr. Neha Shanker DRRI

A holistic approach to targeting breast cancer part II: Micronutrient synergy. Presented by: Dr. Neha Shanker DRRI A holistic approach to targeting breast cancer part II: Micronutrient synergy Presented by: Dr. Neha Shanker DRRI Overview of the previous webinar In the last presentation we talked about: Increase in

More information

Basic Pharmacology. Drugs

Basic Pharmacology. Drugs Basic Pharmacology Drugs Basic Principles Study of drugs Actions Dosage Therapeutic uses (indications) Adverse effects Directly linked to the pathophysiology of a particular disease Drug = a substance

More information

MEASURE SPECIFICATIONS

MEASURE SPECIFICATIONS QOPI REPTING REGISTRY (QCDR) 2018 QOPI 5 QOPI 11 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Combination chemotherapy

More information

MEASURE SPECIFICATIONS

MEASURE SPECIFICATIONS QOPI REPTING REGISTRY (QCDR) 2018 QOPI5 Title Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Description Percentage

More information

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders New Evidence reports on presentations given at EHA/ICML 2011 Bendamustine in the Treatment of Lymphoproliferative Disorders Report on EHA/ICML 2011 presentations Efficacy and safety of bendamustine plus

More information

QUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS

QUALIFIED CLINICAL DATA REGISTRY (QCDR) 2017 MEASURE SPECIFICATIONS QOPI5 Chemotherapy administered to patients with metastatic solid tumor with performance status of 3, 4, or undocumented (Lower Score - Better) Percentage of adult patients with metastatic solid tumors

More information

Daratumumab, a novel human CD38 monoclonal antibody for the treatment of B cell Non Hodgkin Lymphoma

Daratumumab, a novel human CD38 monoclonal antibody for the treatment of B cell Non Hodgkin Lymphoma Daratumumab, a novel human CD38 monoclonal antibody for the treatment of B cell Non Hodgkin Lymphoma Anna Vidal Department of Hemato Oncology IDIBAPS, Barcelona, Spain B cell lymphoid malignancies seen

More information

Nucleotide metabolism

Nucleotide metabolism Nucleotide metabolism Dr. Diala Abu-Hassan, DDS, PhD Medical students-first semester All images are taken from Lippincott s Biochemistry textbook except where noted Purine and pyrimidine structures and

More information

H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS

H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS Each of you should have 37 new cards: 7 orange cards for antimetabolites 11 white cards for miscellaneous drugs (2 DNA synthesis inhibitors, 1 enzyme,

More information